troglitazone has been researched along with Brain Neoplasms in 4 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 5.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 1.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| "However, its expression in brain tumors has not been studied." | 1.31 | Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines. ( Fujieda, M; Kato, M; Nagaya, T; Saito, K; Seo, H; Yoshida, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, CJ | 1 |
| Lai, GM | 1 |
| Chan, CF | 1 |
| Cheng, AL | 1 |
| Yang, YY | 1 |
| Chuang, SE | 1 |
| Spagnolo, A | 1 |
| Grant, EN | 1 |
| Glick, R | 1 |
| Lichtor, T | 1 |
| Feinstein, DL | 1 |
| Coras, R | 1 |
| Hölsken, A | 1 |
| Seufert, S | 1 |
| Hauke, J | 1 |
| Eyüpoglu, IY | 1 |
| Reichel, M | 1 |
| Tränkle, C | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Blümcke, I | 1 |
| Hahnen, E | 1 |
| Kato, M | 1 |
| Nagaya, T | 1 |
| Fujieda, M | 1 |
| Saito, K | 1 |
| Yoshida, J | 1 |
| Seo, H | 1 |
4 other studies available for troglitazone and Brain Neoplasms
| Article | Year |
|---|---|
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Chromans; Cyclin A; | 2006 |
Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Surv | 2007 |
The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chromans; DNA Primers; Dow | 2007 |
Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Blotting, Northern; Brain Neoplasms; Cell Division; C | 2002 |